SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0959 8049 OR L773:1879 0852 "

Sökning: L773:0959 8049 OR L773:1879 0852

  • Resultat 861-870 av 908
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
861.
  • Ringberg, Anita, et al. (författare)
  • Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics
  • 2001
  • Ingår i: European Journal of Cancer. - 1879-0852. ; 37:12, s. 1514-1522
  • Tidskriftsartikel (refereegranskat)abstract
    • All cases of ductal carcinoma in situ (DCIS) diagnosed from 1987 to 1991 in the Southern Health Care Region of Sweden, and operated upon with breast conserving treatment (BCT) with (n=66) or without (n=121) postoperative radiation (RT) were clinically followed, morphologically re-evaluated and analysed for cell biological factors (immunohistochemical assays or DNA flow cytometry). Median age at diagnosis was 58 years (range 29--83 years) and median follow-up was 62 months. Oestrogen (ER)- and progesterone receptor (PR)-negativity, c-erbB-2 overexpression, low bcl-2 expression, p53 accumulation, DNA non-diploidy and high Ki67, were strongly associated with high grade DCIS, and comedo-type necrosis. In contrast, significant associations to growth pattern (not diffuse versus diffuse) were seen only for c-erbB-2 and PgR. There was also a strong relationship between the cell biological factors, and a summary cell biological index based on principal component analysis was introduced (CBI-7). In the group that had not received postoperative RT, 31 ipsilateral local recurrences occurred (13 invasive, 18 DCIS). Ipsilateral recurrence-free interval (IL-RFI) was in univariate analyses significantly, or almost significantly, shorter for patients showing p53 accumulation, high Ki67 or low bcl-2, compared with patients with normal p53, low Ki67 and high bcl-2. The prognostic importance of the remaining cell biological factors was less pronounced. On the other hand, the index CBI-7, was a strong predictor for recurrence.
  •  
862.
  •  
863.
  •  
864.
  •  
865.
  •  
866.
  • Rose, Carsten, et al. (författare)
  • An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole
  • 2003
  • Ingår i: European Journal of Cancer. - 1879-0852. ; 39:16, s. 2318-2327
  • Tidskriftsartikel (refereegranskat)abstract
    • It was previously shown that letrozole (Femara(R)) was significantly more potent than anastrozole (Arimidex(R)) in inhibiting aromatase activity in vitro and in inhibiting total body aromatisation in patients with breast cancer. The objective of this study was to compare letrozole (2.5 mg per day) and anastrozole (1 mg per day) as endocrine therapy in postmenopausal women with advanced breast cancer previously treated with an anti-oestrogen. This randomised, multicentre and multinational open-label phase IIIb/IV study enrolled 713 patients. Treatment was for advanced breast cancer that had progressed either during anti-oestrogen therapy or within 12 months of completing that therapy. Patients had tumours that were either positive for oestrogen and/or progesterone receptors (48%) or of unknown receptor status (52%). The primary efficacy endpoint was time to progression (TTP). Secondary endpoints included objective response, duration of response, rate and duration of overall clinical benefit (responses and long-term stable disease), time to treatment failure, and overall survival, as well as general safety. There was no difference between the treatment arms in TTP; median times were the same for both treatments. Letrozole was significantly superior to anastrozole in the overall response rate (ORR) (19.1% versus 12.3%, P=0.013), including in predefined subgroups (receptor status-unknown, and soft-tissue- and viscera-dominant site of disease). There were no significant differences between the treatment arms in the rate of clinical benefit, median duration of response, duration of clinical benefit, time to treatment failure or overall survival. Both agents were well tolerated and there were no significant differences in safety. These results support previous data documenting the greater aromatase-inhibiting activity of letrozole and indicate that advanced breast cancer is more responsive to letrozole than to anastrozole as second-line endocrine therapy. (C) 2003 Elsevier Ltd. All rights reserved.
  •  
867.
  •  
868.
  •  
869.
  •  
870.
  • Rydbeck, Daniel, et al. (författare)
  • Younger age at onset of colorectal cancer is associated with increased patient's delay
  • 2021
  • Ingår i: European Journal of Cancer. - : Elsevier BV. - 0959-8049. ; 154, s. 269-276
  • Tidskriftsartikel (refereegranskat)abstract
    • Aim: This study aimed to investigate if younger age at diagnosis of colorectal cancer was associated with a diagnostic delay. The secondary objective was to evaluate if symptomatology varied with age. Method: The study population consisted of the cohorts from two prospective multicentre studies conducted in Sweden and Denmark, the QoLiRECT and QoLiCOL studies. These studies investigated the quality of life in patients with colorectal cancer. Participants responded to the validated questionnaires used to extract information on patient's and doctor's delay as well as first presenting symptoms. Clinical variables were retrieved from the Swedish Colorectal Cancer Registry and the Danish Colorectal Cancer Group Database. Results: 2574 patients were included, 1085 from QoLiRECT and 1489 from QoLiCOL. The probability of an increased patient's delay was higher when age decreased by 10 years (the SD in both QoLiRECT and QoLiCOL), adjusted OR 1.19 (95%CI: 1.10; 1.30), p < 0.001. A similar effect was found for doctor's delay, but the age effect was smaller in this case, adjusted OR 1.05 (95%CI: 0.97; 1.15), p Z 0.177. When the age effect was analysed non linearly, an increased probability of a delay was seen for patients from around 60 years and below. Younger patients were equally or more likely to report the symptoms of blood in stool, diarrhoea, constipation, mucus in faeces, faecal urgency, faecal emptying difficulties and pain compared to older patients. Conclusion: Younger patients were more likely to have an increased patient's delay, probably contributing to a delayed diagnosis of colorectal cancer. Symptomatology at diagnosis was similar irrespective of age. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 861-870 av 908
Typ av publikation
tidskriftsartikel (701)
konferensbidrag (194)
forskningsöversikt (13)
Typ av innehåll
refereegranskat (651)
övrigt vetenskapligt/konstnärligt (257)
Författare/redaktör
Bergh, J (24)
Glimelius, Bengt (23)
Lagergren, J (21)
Hemminki, K (20)
Holmberg, Lars (19)
Glimelius, B (17)
visa fler...
Weiderpass, E (16)
Olsson, Håkan (15)
Hall, P (15)
Czene, K (15)
Stattin, Pär (15)
Hemminki, Kari (15)
Ringborg, U (14)
Fernö, Mårten (13)
Johansson, H (13)
Pukkala, E (13)
Borg, Åke (13)
Hjorth, Lars (12)
Sandelin, K (12)
Hansson, J. (12)
Holmberg, L (11)
Nilsson, S. (11)
Sundquist, Jan (11)
Sundquist, Kristina (10)
Kogner, P (10)
Frisell, J (10)
Garmo, H. (10)
Adami, HO (9)
Engholm, G (9)
Wolk, Alicja (9)
Garmo, Hans (9)
Blomqvist, C (8)
Rutqvist, LE (8)
Adolfsson, J. (8)
Nilsson, M (8)
De Boniface, J (8)
Lambe, Mats (8)
Hugosson, Jonas, 195 ... (8)
Hartman, M (8)
Nordenskjöld, Bo (8)
Malmström, Per (7)
Bendahl, Pär Ola (7)
Audisio, Riccardo A (7)
Mellstedt, H (7)
Wärnberg, Fredrik (7)
Möller, Torgil (7)
Bergh, Jonas (7)
Påhlman, Lars (7)
Adolfsson, Jan (7)
Larsson, Susanna C. (7)
visa färre...
Lärosäte
Karolinska Institutet (558)
Uppsala universitet (160)
Lunds universitet (152)
Umeå universitet (70)
Göteborgs universitet (63)
Linköpings universitet (34)
visa fler...
Örebro universitet (31)
Karlstads universitet (7)
Linnéuniversitetet (5)
Kungliga Tekniska Högskolan (2)
Stockholms universitet (2)
Jönköping University (2)
Chalmers tekniska högskola (2)
Marie Cederschiöld högskola (2)
Högskolan i Halmstad (1)
Mälardalens universitet (1)
Handelshögskolan i Stockholm (1)
Mittuniversitetet (1)
Södertörns högskola (1)
Gymnastik- och idrottshögskolan (1)
Högskolan Dalarna (1)
visa färre...
Språk
Engelska (908)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (362)
Naturvetenskap (4)
Samhällsvetenskap (4)
Lantbruksvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy